The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Quiz|Articles|July 17, 2026
OncLive Weekly News Quiz (7/17/2026): Did You Catch Important Milestones in Breast Cancer and Myeloma?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA approved gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for patients with hormone receptor–positive, HER2-negative advanced breast cancer following progression on or after treatment with 1 or more lines of endocrine therapy in the metastatic setting. Which biomarker characteristic defines the indicated population?
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Advertisement
Advertisement
Trending on OncLive
1
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
2
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
3
MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma
4
Neoadjuvant Cemiplimab Elicits Responses and Surgical Benefit in HHI-Naive BCC of the Head and Neck
5